Analyst: Treanda launch won't threaten Rituxan, Revlimid sales

05/27/2008 | CNNMoney

Rituxan, a cancer medicine developed by Genentech and Biogen Idec, will continue to generate strong sales despite the introduction of Cephalon's Treanda because both drugs will probably be used as combination therapy to treat non-Hodgkin's lymphoma, according to a survey conducted by JPMorgan analyst Geoffrey Meacham. The survey, which involved 71 hematologists and cancer specialists, also showed that Treanda's launch will have minimal impact on Celgene Corp.'s Revlimid because the drugs cater to different cancer patients, Meacham said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT